- Atherosclerotic cardiovascular diseases and clinical signifikance of treatment with inclisiran2021 | Faculty of Medicine in Hradec Králové
- New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO)2022 | Faculty of Medicine in Pilsen
- Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)2023 | First Faculty of Medicine
- Lipid lowering therapy - proven treatment options and prospects for the near future2022 | First Faculty of Medicine
- Will it be more effective in cardiovascular events than the monoclonal antibodies against PCSK9?2018 | Faculty of Medicine in Hradec Králové
- The LDL number is alive!2021 | First Faculty of Medicine
- Inclisiran: the first siRNA approved by European Medicines Agency for treatment of dyslipidemias2021 | First Faculty of Medicine
- New lipid lowering drugs2021 | First Faculty of Medicine
- Dyslipidemia - the known unknown2023 | First Faculty of Medicine
- Terapie hyperlipoproteinemií a dyslipidemií na začátku 20.let třetího milénia2021 | First Faculty of Medicine
- What is new in dyslipidemia treatment2020 | Faculty of Medicine in Pilsen
- Treatment of dyslipidemia - where are we and where are we going?2020 | Third Faculty of Medicine
- News in the treatment of dyslipidaemia2019 | First Faculty of Medicine
- Current and future trends in the treatment of dyslipidemias2019 | First Faculty of Medicine
- Nedostatečná korekce hodnot LDL cholesterolu u nemocných s periferní aterosklerózou: jak zlepšit tento stav?2022 | First Faculty of Medicine, Third Faculty of Medicine
